Pfizer to Buy AstraZenca’s Small Molecule Antibiotics Business
Source: BFW (Bloomberg First Word)
Tickers
PFE US (Pfizer Inc)
AZN LN (AstraZeneca PLC)
To de-activate this alert, click here
UUID: 7947283
(Bloomberg) -- Pfizer to acquire the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infectives business, primarily outside the U.S.
Alert: HALISTER- Agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta, Merrem/Meronem and Zinforo
- Under the terms of the agreement, Pfizer will make an upfront payment of $550m to AstraZeneca upon the close of the transaction and a deferred payment of $175m in Jan. 2019
- In addition, AstraZeneca is eligible to receive up to $250m in milestone payments, up to $600m in sales-related payments, as well as tiered royalties on sales of Zavicefta and ATM-AVI in certain markets
Source: BFW (Bloomberg First Word)
Tickers
PFE US (Pfizer Inc)
AZN LN (AstraZeneca PLC)
To de-activate this alert, click here
UUID: 7947283